Status:

COMPLETED

A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Conditions:

Depressive Disorder, Major

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.

Detailed Description

This is an open-label (all people know the identity of the intervention), multi-center, prospective (a study in which the participants are identified and then followed forward in time for the outcome ...

Eligibility Criteria

Inclusion

  • Diagnosis of major depressive disorder according to the American Psychiatric Association's Diagnostic and Statistical Manual-IV, Text Revision (DSM-IV-TR) diagnostic criteria
  • Minimum scores of 9 on Sheehan Disability Scale
  • Minimum scores of 14 on Hamilton Anxiety Scale

Exclusion

  • History of primary or comorbid diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder, or dementia
  • Presence of unstable serious illness and/or has a clinically significant renal or hepatic impairment, seizure disorders or any other disease which may be detrimental to the participant or the study
  • Participant who have continuously taken psychoactive substances, antidepressants, anxiolytics, Monoamine oxidase inhibitors, psychoactive herbal remedies, lithium, electroconvulsive therapy, carbamazepine in the past 2 weeks before the baseline visit
  • Diagnosis of major depressive disorder who currently require treatment systematically within past 2 months from baseline
  • Receiving pharmacological treatment, which is disallowed in the current approved Chinese summary of product characteristics for escitalopram

Key Trial Info

Start Date :

March 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2015

Estimated Enrollment :

261 Patients enrolled

Trial Details

Trial ID

NCT01870843

Start Date

March 1 2014

End Date

May 1 2015

Last Update

July 11 2016

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Beijing, China

2

Guangzhou, China

3

Hangzhou, China

4

Hohhot, China